Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trial

Addex Therapeutics’ neuropsychiatric-focused spinout has raised $105 million in series B funds to bankroll a planned phase 2 study of its schizophrenia treatment.